PRA Health Sciences

PRA Health Sciences is a full-service global contract research organization providing a broad range of product development and data solution services to pharmaceutical and biotechnology companies around the world. PRA Health Sciences' global operations span more than 90 offices across North America, Europe, Asia, Latin America, South Africa, Australia, and the Middle East. PRA’s 17,000+ employees have participated in more than 3,800 clinical trials and have supported pivotal trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 85 products since the year 2000.

Reinvent Technology Partners

Osprey Technology Acquisition Corp

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:

Moore Kuehn Encourages SFTW, PRAH, RTP, and PAND Investors to Contact Law Firm

ICON

ICON plc, (NASDAQ: ICLR) recently announced it entered into a definitive agreement to acquire PRA Health Sciences, Inc. (NASDAQ: PRAH) in a deal valued at $12 billion. These are the details.

ICON (ICLR) To Buy PRA Health Sciences (PRAH) In $12 Billion Deal

NEW YORK, Feb. 24, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of PRA Health Sciences Inc. ("PRAH" or the "Company") (NASDAQ: PRAH) in connection with the proposed cash-and-stock acquisition...

SHAREHOLDER ALERT: WeissLaw LLP Investigates PRA Health Sciences Inc.

MILWAUKEE, Feb. 24, 2021 /PRNewswire/ -- Ademi LLP is investigating PRA Health (NASDAQ: PRAH) for possible breaches of fiduciary duty and other violations of law in its transaction with Icon. Click here to learn how to join the action: http://ademilaw.com/case/pra-health-sciences-inc or...

Shareholder Alert: Ademi LLP Investigates whether PRA Health Sciences, Inc. has obtained a Fair Price in its transaction with Icon

Poseida Therapeutics

Salarius Pharmaceuticals Inc

Sunesis Pharmaceuticals

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biopharma focused on developing targeted therapies for hematologic and solid cancers, filed its annual report on Form 10-K with the SEC.

Why Sunesis, Poseida, Salarius And PRA Health Are Rallying

The company released its fourth-quarter earnings report, but that doesn't tell the whole story.

Why PRA Health Sciences Stock Is Soaring Today

NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of PRA Health Sciences, Inc. (NASDAQ: PRAH) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by ICON plc (NASDAQ: ICLR).

PRA HEALTH SCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRAH and Encourages Investors to Contact the Firm

WILMINGTON, Del., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating PRA Health Sciences, Inc. (“PRA”) (NASDAQ GS: PRAH) regarding possible breaches of fiduciary duties and other violations of law related to PRA's agreement to be acquired by ICON plc (“ICON”) (NASDAQ GS: ICLR). Under the terms of the agreement, PRA's shareholders will receive 0.4125 shares of ICON common stock and $80.00 in cash per share.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of PRA Health Sciences, Inc. Buyout

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of PRA Health Sciences, Inc. (NASDAQ: PRAH) to ICON plc is fair to PRA Health shareholders. Under the terms of the transaction, PRA Health shareholders will receive $80.00 in cash and 0.4125 shares of ICON stock for each PRA Health share that they own. Halper Sadeh encourages PRA Health shareholders to click here to learn more about their legal rights and options or contact Daniel S

PRA Health Sciences Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of PRA Health Sciences, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – PRAH

SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of PRA Health Sciences, Inc. ("PRA" or the "Company") (NASDAQ: PRAH) breached their fiduciary duties in connection with the proposed sale...

(PRAH): Johnson Fistel Investigates the Proposed Sale of PRA Health; Are Shareholders Getting a Fair Deal?

Shares of PRA Health Sciences (NASDAQ:PRAH) rose 20.6% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 0.65% year over year to $1.55, which beat the estimate of $1.47.

Recap: PRA Health Sciences Q4 Earnings

PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 5.44% and 5.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

PRA Health Sciences (PRAH) Beats Q4 Earnings and Revenue Estimates

ICON plc (NASDAQ: ICLR) has agreed to acquire PRA Health Sciences Inc (NASDAQ: PRAH) in a cash and stock transaction valued at approximately $12 billion. The per-share consideration consists of $80 in cash and 0.4125 shares of ICON stock, representing approximately a 30% premium to PRAH's closing price of 127.73 on Tuesday.

ICON Scoops Up PRA Health Sciences In $12B Deal

Icon PLC, a provider of outsourced drug and device development to the drug and medical device industries, said Wednesday it has agreed to acquire PRA Health Sciences Inc. in a cash and stock deal valued at about $12 billion. Under the terms of the deal.

Icon agrees to acquire PRA Health Sciences in cash and stock deal valued at about $12 billion

RALEIGH, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (“PRA,” "we," "us," or the “Company”) (NASDAQ: PRAH) today reported financial results for the quarter and year ended December 31, 2020.

PRA Health Sciences, Inc. Reports Fourth Quarter and Full Year 2020 Results

DUBLIN--(BUSINESS WIRE)--ICON to acquire PRA Health Sciences, creating a world leader in Healthcare Intelligence and Clinical Research

ICON to Acquire PRA Health Sciences, Creating a World Leader in Healthcare Intelligence and Clinical Research

RALEIGH, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 25, 2021. The Company will also host a conference call on Friday, February 26, 2021 at 9:00 a.m. (ET) to discuss the results with members of the investment community.

PRA Health Sciences to Report Fourth Quarter and Full Year 2020 Earnings

PRA Health Sciences selected for the study which will position Awakn at the Forefront of Psychedelic Research for Addiction TreatmentToronto, Ontario--(Newsfile Corp. - January 15, 2021) - Awakn Life Sciences announced today the selection of contract research organization ('CRO'), PRA Health Sciences (NASDAQ: PRAH), to conduct a Phase IIb trial studying the effectiveness of MDMA-Assisted Psychotherapy as a treatment for patients with Non-Physically Dependent ('Harmful Use') Alcohol Use Disorder ("AUD").Awakn's Phase IIb study will take place in the United Kingdom and will be a double-blind, placebo-controlled clinical trial designed to investigate the safety and...

Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder

PRA's remote patient monitoring (RPM) solution now offers a suite of COVID-19 tools – diagnostic testing, clinical monitoring, and symptom reporting and management functionality PRA's remote patient monitoring (RPM) solution now offers a suite of COVID-19 tools – diagnostic testing, clinical monitoring, and symptom reporting and management functionality

PRA Health Sciences collaborates with PWNHealth and Fulgent Genetics to provide at-home COVID-19 test capabilities

PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock?

PRA Health Sciences (PRAH) Down 2.5% Since Last Earnings Report: Can It Rebound?

DexCom

Teladoc

Medical device which has for long taken tiny steps toward IoMT is now going all out to make the most of the advancements in this space amid the pandemic.

IoMT Meets New Healthcare Needs: 3 MedTech Trends to Watch

Dr. Isaac Rodriguez-Chavez brings vast expertise in regulatory compliance and clinical research methodology to PRA's industry-leading DCT practice Dr. Isaac Rodriguez-Chavez brings vast expertise in regulatory compliance and clinical research methodology to PRA's industry-leading DCT practice

PRA Health Sciences appoints senior FDA official to lead new Global Center of Excellence for Decentralized Clinical Trial Strategy

PRA Health Sciences, Inc. (PRAH) CEO Colin Shannon on Q3 2020 Results - Earnings Call Transcript

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.

PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat

PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 15.04% and 3.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

News for PRA Health Sciences Stock (PRAH)